Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 13% Improvement Relative Risk HCQ for COVID-19  Shaw et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? PSM retrospective 144 patients in the USA (March - May 2020) Fewer cases with HCQ (p=0.006) c19hcq.org Shaw et al., J. Drugs in Dermatology, Jul 2021 Favors HCQ Favors control

COVID-19 in Individuals Treated With Long-Term Hydroxychloroquine: A Propensity Score-Matched Analysis of Cicatricial Alopecia Patients

Shaw et al., Journal of Drugs in Dermatology, doi:10.36849/JDD.5843
Jul 2021  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
PSM retrospective 144 alopecia patients in the USA, showing lower risk of COVID-19 with HCQ prophylaxis. The supplemental appendix is not available.
risk of case, 13.0% lower, OR 0.87, p = 0.006, treatment 45, control 99, adjusted per study, propensity score matching, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shaw et al., 1 Jul 2021, retrospective, USA, peer-reviewed, 10 authors, study period 1 March, 2020 - 15 May, 2020.
Contact: Kristen.LoSicco@nyulangone.org.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: doi:10.36849/JDD.5843 To order reprints or e-prints of JDD articles please contact sales@jddonline.com August 2021 914 Volume 20 • Issue 8 Copyright © 2021 LETTERS TO THE EDITOR Journal of Drugs in Dermatology COVID-19 in Individuals Treated With Long-Term Hydroxychloroquine: A Propensity Score-Matched Analysis of Cicatricial Alopecia Patients Katharina S. Shaw,a Lu Yin,a Jinal K. Shah,b Rachel A. Sally,a Katerina S. Svigos,a Prince U. Adotama,a Hsiao Han Tuan,a Jerry Shapiro MD,a Rebecca A. Betensky,b* and Kristen I. Lo Sicco MDa* The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY b Department of Biostatistics, New York University School of Global Public Health, New York, NY a Both authors contributed equally to this work as co-first authors *
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit